For their part, LSD1/KDM1A inhibitors are still in pre-clinical studies for glioblastoma/glioma and medulloblastoma [45,46,47], while they are advancing into the early phase for other clinical indications (hematologic malignancy and solid tumors) [48]. This evidence concerns the gene KDM1A and medulloblastoma.